Status:

COMPLETED

Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?

Lead Sponsor:

Medical University of Vienna

Conditions:

Glaucoma

Eligibility:

All Genders

40+ years

Phase:

NA

Brief Summary

Matrix metalloproteinases (MMPs) fulfill diverse important molecular functions and play pivotal roles in development, tissue morphogenesis, repair, aging, and inflammatory processes. MMPs are also imp...

Eligibility Criteria

Inclusion

  • Men and women older than 39 years
  • Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
  • Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)

Exclusion

  • Exfoliation glaucoma, pigmentary glaucoma
  • History of acute angle closure

Key Trial Info

Start Date :

November 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2009

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT00312403

Start Date

November 1 2005

End Date

December 1 2009

Last Update

January 15 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Clinical Pharmacology

Vienna, Austria, 1090